This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT07508241 |
|---|---|
| Status | Active not recruiting |
| Phase | Phase 1 |
| Sponsor | Pfizer |
| Enrollment | 22 participants |
| Design | Interventional, Na, Single Group, Masking: None |
| Conditions | Obesity; Overweight and/or Obesity; Overweight; Drug Interaction |
| Interventions | PF-08653944; Acetaminophen |
| Start | Mar 31, 2026 |
| Primary completion | Jan 27, 2027 |
| Study completion | Jan 27, 2027 |
| Results posted | Not yet |
| Registry last updated | Jul 9, 2026 |
Compounds on this site that cite this trial
What the registry says the trial is about
This study looks at how a study medicine called PF-08653944 affects how quickly the stomach empties food after eating. It is being done in adults who are overweight or have obesity.
Participants will receive the study medicine for a short period, and doctors will measure how the medicine moves through the stomach and monitor safety. The goal is to better understand how this medicine works in the body and to check for any side effects.
The information from this study may help researchers plan future studies of this medicine.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Acetaminophen Pharmacokinetic (PK) Parameters: Maximum observed plasma concentration (Cmax) | Day 1 pre-dose through approximately 11 Weeks after last dose of study intervention. |
| Acetaminophen PK parameters: Area under the plasma concentration (AUC) | Day 1 pre-dose through approximately 11 Weeks after last dose of study intervention. |
| Acetaminophen PK parameters: Time to Maximum concentration (Tmax) | Day 1 pre-dose through approximately 11 Weeks after last dose of study intervention. |
1 secondary outcome also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Nov 17, 2026. See the trial changes feed for what has changed recently.
More trials of Berobenatide
- A Study to Learn How the Study Medicine Called PF-08653944 is Taken up Into the Blood (Phase 1 NCT07400679)
- A Study to Learn About the Medicine Called PF-08653944 in People With and Without Reduced Liver (Phase 1 NCT07519135)
More from Pfizer
- VESPER-OSA 2: sleep apnea without airway pressure therapy (Phase 3 NCT07881757)
- Once-monthly berobenatide in Chinese adults (Phase 3) (Phase 3 NCT07874633)
- VESPER-JW: once-weekly berobenatide in Japan (Phase 3 NCT07794761)
- VESPER-SWITCH: monthly berobenatide for weight maintenance (Phase 3 NCT07845500)
Research area: Metabolic and incretin. Every registered trial we follow is in the clinical trial tracker, and the labels used on this page are explained in our evidence standards.